Therefore , we determined the effect of OL-1 to inhibit the activation of PARP1 and downstream substrate proteins such as PAR in treated cells by western blot analysis. to impact future TNBC therapy. == Introduction == Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved enzyme focused on the self-repair of cellular DNA damage, participating in several biological processes including apoptosis, chromosome stability, gene amplification, transcriptional regulation and cell division1, 2 . When DNA damage occurs, PARP1 senses and binds to the site of Single-strand breaks (SSBs) and becomes catalytically activated. It utilizes nicotinamide adenine dinucleotide (NAD+) as substrate to form branching chains of poly (ADP-ribose) (PAR) onto PARP1 itself as well as other nuclear proteins or enzymes including histones, DNA topoisomerases, ligases and polymerases3, 4. Synthesized PAR chains recruit X-ray repair cross-complementing protein 1 (XRCC1), DNA ligase III and DNA polymerase to DNA damage sites, subsequently mediating base excision repair (BER)5. Inhibition of PARP1 will lead to the accumulation of SSBs and stalling of DNA repair machinery, finally resulting in double-strand breaks (DSBs)6. Interestingly, over-expressed PARP1 has been demonstrated in various cancers such as melanomas, glioblastoma and breast cancer711. Moreover, high expression level of PARP1 was found closely related with triple-negative breast cancer (TNBC)12. Consequently, targeting PARP1 and inhibiting its relevant biological function may be another avenue of breast cancer therapy, especially for TNBC. Previous studies have been reported that inhibition of PARP1 leads to synthetic lethality in some BRCA1/2 mutant cancers (including ovarian and breast cancer), which could be specifically targeted by PARP1 inhibitors13. Currently, various PARP inhibitors, such as Olaparib, Rucaparib, BMN-673, Niraparib and Iniparib (Fig. 1), are under development indifferent stages of S38093 HCl clinical trial1420. From a chemical point of view, most chemical scaffolds of PARP inhibitors contain amide structure, more new chemical structures S38093 HCl can be found in the future21, 22; From a biological point of view, although these PARP inhibitors have high PARP1/2 inhibition and anti-tumor activity; however , long-term drug administration will accompany with drug resistance, leading to tumor recurrence and metastasis23. Thus, in addition to explore the in-depth drug resistance mechanism of existing inhibitors, as well as the relationship between PARP-mediated signaling pathways and tumor specificity, developing a new type PARP inhibitor with improved therapeutic efficacy and lower toxicity is alternatively promising strategy for TNBC therapy. == Figure 1 . == PARP inhibitors in clinical trial. With the rapid development of computational methods and structural biology, many studies successfully identifying epigenetic inhibitors using pharmacophore-docking-based virtual screening and co-crystallization studies have been reported2426. In this study, by constructing a pharmacophore of PARP1 inhibitor and screening a new chemical skeleton through co-crystallization studies, we designed and synthesized several series of PARP1 inhibitors, then identified a novel PARP1 inhibitor (OL-1). This inhibitor could significantly induce cell death and inhibit cell migration inBRAC1mutant MDA-MB-436 cells with potent S38093 HCl anti-tumor efficacyin vivo. These findings highlight a new small-molecule PAPR1 inhibitor (OL-1) that has the potential to impact future TNBC therapy. == Results and Discussion == == Co-crystallization screening and structure-based pharmacophore of PARP1/inhibitor complex == Numbers of PARP inhibitors have been reported over the past several years, such as Olaparib, Rucaparib, BMN 673, Niraparib and Iniparib (Fig. 1)2729. These previous work had well described that PARP inhibitors occupy the nicotinamide pocket in the NAD+binding site of PARP1, forming key hydrogen bonds and – interactions. Firstly, we used virtual screening of chemical libraries that based upon Drugbank and ZINC databases, searching for novel leading compounds with distinctive skeleton (Fig. 2A). Top500 hits were selected by LibDock protocol in the first step. Subsequently, Top100 (PA-1 ~ PA-100) hits were further determined by CDOCKER protocol and selected for co-crystallization screening. As a result, only one compound from Drugbank database (DB00321) named as PA-10 (3-(10, 11-dihydro-5H-dibenzo[a, d][7]annulen-5-ylidene)-N, N-dimethylpropan-1-amine) bound to the nicotinamide pocket of PARP1 (PDB ID code 5HA9) in the co-crystallization screening (Fig. 2B). To explore how to modify the leading compound, we constructed the structure-based pharmacophore including ten reported co-crystal structures of PARP inhibitors. The detected pharmacophore features were Rabbit polyclonal to LRRIQ3 shown in Table1and Fig. 2C. Among these features, four of them were found as common in these complexes, including A1 (hydrogen bond acceptor), D1 (hydrogen bond donor), AR1 (ring aromatic) and H1 (hydrophobic) (Fig. 2D). Therefore , we can further modify the leading compound by increasing the length of carbon chain; increasing substituent containing hydrogen bond donor and changing of aromatic skeleton. And all newly synthesized compounds were designed according to abovementioned structure-based pharmacophore features. == Figure 2 . == Crystal structure, pharmacophore models construction and molecular docking of PARP1 inhibitors. (A) Virtual screening schematic model for the discovery process.